- Home
- BOLT vs GOVX Comparison
BOLT vs GOVX Comparison
Compare BOLT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- GOVX
- Stock Information
- Founded
- BOLT 2015
- GOVX 2001
- Country
- BOLT United States
- GOVX United States
- Employees
- BOLT N/A
- GOVX N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- GOVX Health Care
- Exchange
- BOLT Nasdaq
- GOVX Nasdaq
- Market Cap
- BOLT 9.4M
- GOVX 7.6M
- IPO Year
- BOLT 2021
- GOVX N/A
- Fundamental
- Price
- BOLT $5.19
- GOVX $0.70
- Analyst Decision
- BOLT Buy
- GOVX Strong Buy
- Analyst Count
- BOLT 3
- GOVX 3
- Target Price
- BOLT $47.50
- GOVX $10.67
- AVG Volume (30 Days)
- BOLT 14.4K
- GOVX 721.4K
- Earning Date
- BOLT 08-14-2025
- GOVX 07-28-2025
- Dividend Yield
- BOLT N/A
- GOVX N/A
- EPS Growth
- BOLT N/A
- GOVX N/A
- EPS
- BOLT N/A
- GOVX N/A
- Revenue
- BOLT $4,167,000.00
- GOVX $6,143,044.00
- Revenue This Year
- BOLT N/A
- GOVX N/A
- Revenue Next Year
- BOLT N/A
- GOVX N/A
- P/E Ratio
- BOLT N/A
- GOVX N/A
- Revenue Growth
- BOLT N/A
- GOVX 1943.07
- 52 Week Low
- BOLT $4.59
- GOVX $0.43
- 52 Week High
- BOLT $14.36
- GOVX $4.29
- Technical
- Relative Strength Index (RSI)
- BOLT 46.64
- GOVX 41.96
- Support Level
- BOLT $4.81
- GOVX $0.71
- Resistance Level
- BOLT $5.28
- GOVX $0.77
- Average True Range (ATR)
- BOLT 0.26
- GOVX 0.05
- MACD
- BOLT 0.01
- GOVX -0.00
- Stochastic Oscillator
- BOLT 70.26
- GOVX 19.32
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.